Abbott Receives CE Mark for FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System™

  Abbott Receives CE Mark for FreeStyle Optium Neo Blood Glucose and Ketone
                              Monitoring System™

  PR Newswire

  ABBOTT PARK, Illinois, Sept. 17, 2013

ABBOTT PARK, Illinois, Sept. 17, 2013 /PRNewswire/ -- Abbott (NYSE: ABT)
announced today it has received CE Marking (Conformite Europeenne) in Europe
for the FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System™. The
new icon-driven system provides sleek design, visual glucose trend indicators
and insulin logging – all delivered in a single device to support daily
diabetes management.

According to the World Health Organization, the prevalence of diabetes is
increasing in the European region. Nearly 20 percent of women and men aged 25
years and older in Europe are living with diabetes[i], which makes diabetes
one of the most prevalent chronic conditions.

Features of Abbott's FreeStyle Optium Neo System include:

  *A high contrast, icon-driven display designed for ease-of-use
  *Small, sleek meter design
  *Blood glucose trend indicators, which visually notify patients when they
    are experiencing hypo- or hyperglycemic trends (low or high blood glucose
    levels)
  *An insulin dose feature, which allows healthcare professionals to program
    a patient's insulin plan into the meter. Beginning from the physician's
    recommendation in the dose guide, the meter is designed to allow patients
    to log actual insulin doses by tapping the arrows up or down. This feature
    is designed to enable patients and their healthcare professionals to
    review logged insulin doses along with glucose results.

"The FreeStyle Optium Neo System is our latest advance based on the innovative
technology that is at the heart of both our Precision and Optium products. It
combines powerful features, ease-of-use and the ability to analyze important
glucose trends in a single device," said Heather Mason, senior vice president,
Diabetes Care, Abbott. "The device's advanced design and technology enables
the ability to track glucose trends and log insulin, which may help improve
the patient's daily diabetes management. This system is one more example of
how Abbott is focused on meeting the needs of patients."

The system is designed to be used with FreeStyle Optium blood glucose and
ketone test strips, which are currently available in Europe. Abbott recently
marked the 25th anniversary of its invention of commercial biosensor
technology for diabetes patients, the forerunner of today's FreeStyle
Precision and FreeStyle Optium strips.

Abbott's FreeStyle Optium Neo System will be available throughout Europe in
the coming weeks. Individuals with diabetes who are interested in the
FreeStyle Optium Neo System should consult with their healthcare professional.

About Abbott Diabetes Care

Abbott Diabetes Care, based in Alameda, California, is a leader in developing,
manufacturing and marketing glucose monitoring systems designed to help people
better manage their diabetes. Additional information about Abbott Diabetes
Care may be found at www.abbottdiabetescare.com .

About Abbott

Abbott is a global healthcare company devoted to improving life through the
development of products and technologies that span the breadth of healthcare.
With a portfolio of leading, science-based offerings in diagnostics, medical
devices, nutritionals and branded generic pharmaceuticals, Abbott serves
people in more than 150 countries and employs approximately 70,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

[i] World Health Organization. Accessed August 2013.
http://www.euro.who.int/en/what-we-do/health-topics/noncommunicable-diseases/diabetes/facts-and-figures

Website: http://www.abbott.com
Contact: Media, Jonathon Hamilton, +1-(847)-935-8646, or Jessica Sachariason,
+1-(510)-239-2690, or Financial, Tina Ventura, +1-(847)-935-9390
 
Press spacebar to pause and continue. Press esc to stop.